Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion

Acta Haematologica

Volumn 113, Issue 2, 2005, Pages 146-149

  Giagounidis, A A N ^a   Haase, S ^a   Germing, U ^b   Heinsch, M ^a   Aul, C ^a  

^a ST JOHANNES HOSPITAL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

5q anomaly; Autoimmune diseases; Myelodysplastic syndromes

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEFEROXAMINE; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; STEROID;

5Q- SYNDROME; ADULT; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CHROMOSOME BAND; CHROMOSOME DELETION 5; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; HUMAN; LEUKOPENIA; LONG TERM CARE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TRISOMY 21; CHROMOSOME 5; CHROMOSOME DELETION; GENETICS; MIDDLE AGED; REMISSION; TRISOMY;

ADRENAL CORTEX HORMONES; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; TRISOMY;

EID: 17144407664     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083454     Document Type: Article

References (23)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC, 2001.
2. Boultwood J, Lewis S, Wainscoat JS: The 5q-syndrome. Blood 1994;84:3253-3260.
3. Heim S, Mitelman F: Chromosome abnormalities in the myelodysplastic syndromes. Clin Haematol 1986;15:281-319.
4. Ohno T, Hishizawa M, Sugiyama T, Mizumoto T, Furukawa H: The 5q-syndrome associated with marked erythroid hypoplasia and Coombs test positive hemolysis (in Japanese). Rinsho Ketsueki 1999;40:499-504.
5. Enright H, Miller W: Autoimmune phenomena in patients with myelodysplastic syndromes. Leuk Lymphoma 1997;24:483-489.
6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
7. Smith MA, Smith JG: The occurrence subtype and significance of haematopoietic inhibitory T cells (HIT cells) in myelodysplasia: An in vitro study. Leuk Res 1991;15:597-601.
8. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, Liu J, Nakamura R, Young NS, Barrett AJ: Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002;137:156-163.
9. Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S: Novel insights into the biology of myelodysplastic syndromes: Excessive apoptosis and the role of cytokines. Int J Hematol 1996;63:265-278.
10. Mundle S, Ali A, Cartlidge JD, Reza S, Alvi S, Showel MM, Mativi BY, Shetty VT, Venugopal P, Gregory SA, Raza A: Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Med 1996;60:36-47.
11. Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA: Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 1986;63:143-147.
12. Colombat PH, Renoux M, Lamagnere JP, Renoux G: Immunologic indices in myelodysplastic syndromes. Cancer 1988;61:1075-1081.
13. Rosenthal NS, Farhi DC: Bone marrow findings in connective tissue disease. Am J Clin Pathol 1989;92:650-654.
14. Hebbar M, Brouillard M, Wattel E, Decoulx M, Hatron P-Y, Devulder B, Fenaux P: Association of myelodysplastic syndrome and relapsing polychondritis: Further evidence. Leukemia 1995;9:731-733.
15. Fernandez-Miranda C, Garcia-Marcilla A, Martin M, Gill R, Vanaclocha F, Torres N, Del Palacio A: Vasculitis associated with a myelodysplastic syndrome. A report of five cases (in Spanish). Med Clin (Bare) 1994;103:539-542.
16. Castro M, Conn DL, Su WP, Garton J: Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 1992;18:721-727.
17. George SW, Newman ED: Seronegative inflammatory arthritis in the myelodysplastic syndromes. Semin Arthritis Rheum 1992;1:345-354.
18. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, Wilkens L, Heinsch M, Willems H, Aivado M, Aul C: Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004;18:113-119.
19. Salama A, Mueller-Eckhardt C: Two types of delayed hemolytic transfusion reactions (discussion). Transfusion 1985;22:182-183.
20. Juneja HS, Jodhani M, Gardner FH, Trevarthen D, Schottstedt M: Low-dose Ara-C consistently induces hematologic responses in the clinical 5q-syndrome. Am J Hematol 1994;46:338-342.
21. Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N: Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002;16:1-6.
22. List AF, Kurtin SE, Glinsmann-Gibson BJ, Bellamy WT, Buresh AJ, Waddleton D, Knight R: High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS). Blood 2002;100:96a.
23. Mathew P, Tefferi A, Dewald GW, Goldberg SL, Su J, Hoagland HC, Noel P: The 5q-syndrome: A single-institution study of 43 consecutive patients. Blood 1993;81:1040-1045.